ALKS Alkermes plc

Price (delayed)

$24.66

Market cap

$3.96B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.6

Enterprise value

$4.18B

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by ...

Highlights
Alkermes's net income has increased by 32% YoY and by 15% from the previous quarter
The EPS is up by 32% year-on-year and by 14% since the previous quarter
ALKS's quick ratio is up by 2.9% since the previous quarter but it is down by 2.3% year-on-year
Alkermes's gross profit has decreased by 14% YoY
The revenue has contracted by 13% YoY

Key stats

What are the main financial stats of ALKS
Market
Shares outstanding
160.45M
Market cap
$3.96B
Enterprise value
$4.18B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.74
Price to sales (P/S)
3.77
EV/EBIT
N/A
EV/EBITDA
615.18
EV/Sales
4
Earnings
Revenue
$1.04B
EBIT
-$74.09M
EBITDA
$6.8M
Free cash flow
$48.38M
Per share
EPS
-$0.6
Free cash flow per share
$0.3
Book value per share
$6.6
Revenue per share
$6.54
TBVPS
$10.55
Balance sheet
Total assets
$1.88B
Total liabilities
$827.07M
Debt
$429.04M
Equity
$1.05B
Working capital
$640.17M
Liquidity
Debt to equity
0.41
Current ratio
2.75
Quick ratio
2.14
Net debt/EBITDA
32.96
Margins
EBITDA margin
0.7%
Gross margin
83.5%
Net margin
-9.1%
Operating margin
-8.8%
Efficiency
Return on assets
-5%
Return on equity
-8.9%
Return on invested capital
-5%
Return on capital employed
-4.9%
Return on sales
-7.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALKS stock price

How has the Alkermes stock price performed over time
Intraday
0.12%
1 week
-0.16%
1 month
10.78%
1 year
43.54%
YTD
23.61%
QTD
32.01%

Financial performance

How have Alkermes's revenue and profit performed over time
Revenue
$1.04B
Gross profit
$871.84M
Operating income
-$91.49M
Net income
-$94.63M
Gross margin
83.5%
Net margin
-9.1%
Alkermes's operating income has increased by 33% YoY and by 19% from the previous quarter
Alkermes's net income has increased by 32% YoY and by 15% from the previous quarter
The company's operating margin rose by 23% YoY and by 19% QoQ
The net margin has grown by 22% YoY and by 15% from the previous quarter

Growth

What is Alkermes's growth rate over time

Valuation

What is Alkermes stock price valuation
P/E
N/A
P/B
3.74
P/S
3.77
EV/EBIT
N/A
EV/EBITDA
615.18
EV/Sales
4
The EPS is up by 32% year-on-year and by 14% since the previous quarter
The P/B is 33% higher than the last 4 quarters average of 2.8 but 22% lower than the 5-year quarterly average of 4.8
ALKS's P/S is 40% below its 5-year quarterly average of 6.3 but 40% above its last 4 quarters average of 2.7
The revenue has contracted by 13% YoY

Efficiency

How efficient is Alkermes business performance
The ROIC has increased by 44% YoY and by 18% from the previous quarter
The ROA rose by 36% YoY and by 15% QoQ
The return on equity has increased by 31% year-on-year and by 14% since the previous quarter
The ROS is up by 26% year-on-year and by 16% since the previous quarter

Dividends

What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALKS.

Financial health

How did Alkermes financials performed over time
Alkermes's total assets is 127% higher than its total liabilities
The current ratio has grown by 9% from the previous quarter and by 2.2% YoY
The company's total liabilities rose by 8% YoY but it fell by 6% QoQ
The debt is 59% less than the equity
The debt to equity is up by 11% YoY and by 8% from the previous quarter
The debt has grown by 9% YoY and by 4.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.